CDKN2AIP was initially identified as the binding partner or ARF and several studies showed that CDKN2AIP amplification can enhance angiogenesis and its expression was closely associated with higher expression of several markers involved in angiogenesis and metastasis in breast, skin, prostate, liver and kidney cancer [55]. This evidence concerns the gene CDKN2AIP and kidney cancer.